ASC’s Webinar Series: High Throughput and Automated iPSC Genome Editing Platform for Basic Research, Disease Modeling and Drug Screening | ASC

Applied StemCell (ASC) webinar on its acclaimed stem cell genome editing service highlights the generation of physiologically relevant in vitro models using iPSCs and CRISPR/ Cas9.

Title: iPSC Genome Editing Rapid Automated Cell Line Editing (RACE™)

Presenter: Ruby Yanru Chen-Tsai, PhD, CEO and President of Applied StemCell

 

Topics covered in this webinar:

• Integrated end-to-end-solutions for iPSC related projects

• Isogenic cell line model development

• High throughput genome editing with automation and workflow optimization

• Examples of gene modifications in patient and healthy iPSCs

• Downstream differentiation to various lineages

 

This webinar is ideal for researchers working on:

• Rare diseases

• Developmental biology

• Cell therapy and regenerative medicine

• Biotechnology and pharmaceutical companies interested in drug screening in physiologically relevant cell line models

 

This webinar showcases our ability to induce or correct mutation in control or disease iPSC lines, with standard genetic modifications (such as knockout, knock-in, and point mutation) or complex genome engineering such as gene fusion. Furthermore, our high throughput automated process enables higher volume projects, better picking accuracy, reduced hands-on time and errors leading up to 60% faster project timelines and 98% success rate. Applied StemCell also offers control iPSC lines with proven genome editing and differentiation capacity, and downstream differentiation to many cell lineages.

For more details on our stem cell platform, please explore our website or contact us at info@appliedstemcell.com.

 

About Applied StemCell, Inc.

Applied StemCell, Inc. (ASC) is a fast-growing Gene & Cell Therapy CRO headquartered in California, USA. ASC was founded in 2008 with a goal to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. With more than 12 years of experience in genome editing and stem cell technologies, ASC is proud to develop innovative technology platforms offering services and products in the field of Stem Cells (iPSCs/ESCs, differentiated cells) and animal/cell models for disease modeling, antibody discovery & screening, bioproduction, AAV potency assays, cell therapy and regenerative medicine. Our Cell and Gene Therapy Bioservice platform also includes consultation for Pre-IND filing and CMC processes.

 

Media Contact:

Maki Ogawa

Marketing Director, Applied StemCell, Inc.

408-773-8007

maki.ogawa@appliedstemcell.com

Google